Hospitals return to court over HHS plan to turn 340B discounts into rebates
Hospitals are again asking a federal court to stop the government from converting 340B drug discounts into a rebate program, setting up a second legal fight over one of the most contested corners of federal drug pricing policy. The complaint, filed Friday by the American Hospital Association, the Maine Hospital Association, and several safety-net hospitals, seeks to block a revised pilot scheduled to begin in January.
The case lands at the intersection of drug pricing, hospital finance, and patient access. Under the existing 340B structure, eligible providers buy outpatient drugs at steep upfront discounts and keep the difference between acquisition cost and payment as a way to stretch scarce resources. For hospitals serving large numbers of low-income and uninsured patients, those margins can help support charity care, outpatient services, and other parts of the safety net that rarely cover their own costs.
A rebate model changes the cash flow immediately. Instead of receiving the discount at purchase, hospitals would pay up front and wait for reimbursement after the fact. For institutions already operating with thin margins, even a temporary gap in cash flow can create real operational pressure: borrowing costs rise, reserves get tapped, and administrators must reconcile complex claims data before money returns to the hospital.
The revised pilot revives a fight regulators thought they had already lost
This is the second attempt by the Health Resources and Services Administration to launch a 340B rebate pilot, and the second time hospitals have sued to stop it. A previous effort was struck down by a judge after the AHA and the Maine Hospital Association challenged the plan. HRSA then returned with a refreshed version earlier this summer, expanding the list of manufacturers and drugs covered under the pilot.
The hospital groups say that change only deepened the burden. Their complaint argues that HRSA underestimated the administrative and financial demands the program would impose on safety-net providers. In the filing, the agency’s cost analysis is described as “egregiously flawed,” with hospitals saying it leaves out startup expenses, information technology, training, vendor fees, and the work required to reconcile rebates with drug purchases.
HRSA estimated the program would cost $537 million a year. The hospitals contend the true bill could exceed $1 billion annually once the hidden costs of implementation are counted.
One sentence in the complaint captures the core of the dispute. The hospitals say many providers would have to use limited cash reserves to pay for drugs before rebates arrive.
Cash flow, not just accounting, sits at the center of the lawsuit
That issue matters because 340B hospitals are not arguing only about totals on a spreadsheet. They are arguing about timing, liquidity, and the operational reality of maintaining drug access while waiting for repayment. A hospital that has to front the cost of high-volume outpatient medications may face immediate pressure on payroll, pharmacy purchasing, and day-to-day clinical operations long before any rebate is processed.
Safety-net hospitals say the current 340B model exists precisely to protect those margins. By giving providers access to discounted outpatient drugs at the point of purchase, the program allows them to preserve capital for uncompensated care and services for patients who may have no realistic ability to pay. A rebate system, by contrast, shifts risk to the provider and forces hospitals to finance the gap themselves.
The lawsuit also points to broader financial strain. The hospitals say the rebate pilot would land while Medicaid cuts and inflation continue to squeeze operating budgets. In that setting, even a policy framed as an accounting change can have clinical consequences if it alters staffing, infusion capacity, pharmacy inventory, or the availability of outpatient services in vulnerable communities.
Maine hospital leaders framed the problem in stark terms. Jeff Austin, president of the Maine Hospital Association, said Maine hospitals already operate with an average of less than two weeks cash on hand, warning that the new costs could jeopardize care for the most vulnerable patients and affect affordability and access across the state.
Drugmakers want tighter controls as 340B spending keeps rising
Pharmaceutical companies have argued for years that the program has expanded beyond its original purpose. They say some hospitals are profiting excessively from discounted drug purchases and, in some cases, using duplicative discounts in ways that inflate savings. They point to rising 340B spending as evidence the program needs stronger limits.
Last year, hospitals and outpatient facilities purchased $100 billion worth of 340B drugs, a 23% increase from the year before. Drugmakers cite that growth as proof the program’s scope has widened sharply, while hospitals argue the spending reflects rising drug costs, expanding outpatient treatment, and the increasing complexity of caring for underserved populations.
The political backdrop has shifted as well. The Biden administration clashed with manufacturers over proposed rebate plans and defended the traditional upfront discount structure. The Trump administration took a harder line on how 340B discounts are paid, cutting program payments and pushing the rebate pilot forward.
For hospitals, the legal question is narrower than the policy fight around it. They say HHS cannot launch a change of this size without fully accounting for the practical costs and community consequences. The complaint argues that the agency ignored hundreds of public comments warning that the pilot could strain safety-net providers, hurt patient access, and force hospital closures.
The AHA’s president and CEO, Steve Walsh, said the government must consider what the change will mean for the patients and communities that rely on 340B hospitals every day.
For now, the dispute returns to Maine district court, where the hospitals are seeking to halt the January launch before the pilot can begin. The named plaintiffs include Eastern Maine Medical Center, Nathan Littauer Hospital and Nursing Home in New York, Unity Medical Center in North Dakota, and Dallas County Medical Center in Arkansas, alongside the AHA and the Maine Hospital Association.
The court will now have to weigh whether a rebate pilot designed to tighten oversight of 340B can proceed while hospitals argue that the program itself could damage the very providers it was meant to support.